{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,8]],"date-time":"2026-09-08T22:28:03Z","timestamp":1788906483362,"version":"build-2803163510"},"reference-count":39,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,8,15]],"date-time":"2023-08-15T00:00:00Z","timestamp":1692057600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100005668","name":"Funda\u00e7\u00e3o de Apoio \u00e0 Pesquisa do Distrito Federal","doi-asserted-by":"publisher","award":["FINATEC 7044"],"award-info":[{"award-number":["FINATEC 7044"]}],"id":[{"id":"10.13039\/501100005668","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100005668","name":"Funda\u00e7\u00e3o de Apoio \u00e0 Pesquisa do Distrito Federal","doi-asserted-by":"publisher","award":["7155"],"award-info":[{"award-number":["7155"]}],"id":[{"id":"10.13039\/501100005668","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.es","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Anais Brasileiros de Dermatologia"],"published-print":{"date-parts":[[2024,1]]},"DOI":"10.1016\/j.abd.2023.03.002","type":"journal-article","created":{"date-parts":[[2023,8,25]],"date-time":"2023-08-25T11:01:57Z","timestamp":1692961317000},"page":"34-42","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":16,"title":["Elevated serum IL-6 levels predict treatment interruption in patients with moderate to severe psoriasis: a 6-year real-world cohort study"],"prefix":"10.1016","volume":"99","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0445-3448","authenticated-orcid":false,"given":"Nat\u00e1lia Ribeiro de Magalh\u00e3es","family":"Alves","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5759-2727","authenticated-orcid":false,"given":"Patr\u00edcia Shu","family":"Kurizky","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8182-5121","authenticated-orcid":false,"given":"Licia Maria Henrique","family":"da Mota","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9245-7504","authenticated-orcid":false,"given":"Cleandro Pires","family":"de Albuquerque","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3982-2306","authenticated-orcid":false,"given":"Juliana Tomaz","family":"Esper","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8261-1662","authenticated-orcid":false,"given":"Aridne Souza Costa","family":"Campos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0303-851X","authenticated-orcid":false,"given":"Vitoria Pereira","family":"Reis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7007-3147","authenticated-orcid":false,"given":"Henrique Metzker","family":"Ferro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1011-2255","authenticated-orcid":false,"given":"Natalia","family":"Gil-Jaramillo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0248-1138","authenticated-orcid":false,"given":"Joaquim Pedro","family":"Brito-de-Sousa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3362-7902","authenticated-orcid":false,"given":"Luana Cabral Le\u00e3o","family":"Leal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1775-7176","authenticated-orcid":false,"given":"Ot\u00e1vio de Toledo","family":"N\u00f3brega","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1788-9745","authenticated-orcid":false,"given":"Carla Nunes de","family":"Ara\u00fajo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8485-2603","authenticated-orcid":false,"given":"Agenor de Castro Moreira dos","family":"Santos J\u00fanior","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9913-2238","authenticated-orcid":false,"given":"Gladys Aires","family":"Martins","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5494-4889","authenticated-orcid":false,"given":"Olindo Assis","family":"Martins Filho","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3069-6884","authenticated-orcid":false,"given":"Ciro Martins","family":"Gomes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.abd.2023.03.002_bib0005","doi-asserted-by":"crossref","first-page":"1559","DOI":"10.1001\/archderm.143.12.1559","article-title":"Incidence and risk factors for psoriasis in the general population","volume":"143","author":"Huerta","year":"2007","journal-title":"Arch Dermatol."},{"key":"10.1016\/j.abd.2023.03.002_bib0010","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1016\/j.jaad.2018.11.057","article-title":"Joint AAD-NPF guidelines of care for the management and treatment of psoriasis with biologics","volume":"80","author":"Menter","year":"2019","journal-title":"J Am Acad Dermatol."},{"key":"10.1016\/j.abd.2023.03.002_bib0015","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1001\/jamadermatol.2019.4029","article-title":"Comparison of biologics and oral treatments for plaque poriasis: a meta-analysis","volume":"156","author":"Armstrong","year":"2020","journal-title":"JAMA Dermatol."},{"key":"10.1016\/j.abd.2023.03.002_bib0020","article-title":"Systemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysis","volume":"1","author":"Sbidian","year":"2020","journal-title":"Cochrane Database Syst Rev."},{"key":"10.1016\/j.abd.2023.03.002_bib0025","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1016\/S0140-6736(19)31772-6","article-title":"Psoriasis biologics: a new era of choice","volume":"394","author":"Mahil","year":"2019","journal-title":"Lancet."},{"key":"10.1016\/j.abd.2023.03.002_bib0030","first-page":"247","article-title":"Latest advances for the treatment of chronic plaque psoriasis with biologics and oral small molecules","volume":"15","author":"Bellinato","year":"2021","journal-title":"Biologics."},{"key":"10.1016\/j.abd.2023.03.002_bib0035","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1159\/000096196","article-title":"Psoriasis therapy in real life: the need for registries","volume":"213","author":"Schmitt-Egenolf","year":"2006","journal-title":"Dermatology."},{"key":"10.1016\/j.abd.2023.03.002_bib0040","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0244620","article-title":"Real-world efficacy of biological agents in moderate-to-severe plaque psoriasis: An analysis of 75 patients in Taiwan","volume":"15","author":"Chen","year":"2020","journal-title":"PLoS One."},{"key":"10.1016\/j.abd.2023.03.002_bib0045","doi-asserted-by":"crossref","first-page":"1100","DOI":"10.1111\/jdv.13634","article-title":"Psoriasis registries worldwide: systematic overview on registry publications","volume":"30","author":"Eissing","year":"2016","journal-title":"J Eur Acad Dermatol Venereol."},{"key":"10.1016\/j.abd.2023.03.002_bib0050","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1016\/j.abd.2020.08.011","article-title":"Survival of immunobiological drugs in psoriasis: preliminary data from a Tertiary Hospital experience in Southern Brazil","volume":"96","author":"Lima","year":"2021","journal-title":"An Bras Dermatol."},{"key":"10.1016\/j.abd.2023.03.002_bib0055","doi-asserted-by":"crossref","first-page":"579","DOI":"10.3389\/fimmu.2018.00579","article-title":"Systemic Inflammation and Cardiovascular Comorbidity in Psoriasis Patients: Causes and Consequences","volume":"9","author":"Boehncke","year":"2018","journal-title":"Front Immunol."},{"key":"10.1016\/j.abd.2023.03.002_bib0060","doi-asserted-by":"crossref","first-page":"840","DOI":"10.1111\/bjd.18245","article-title":"Management of psoriasis as a systemic disease: what is the evidence?","volume":"182","author":"Korman","year":"2020","journal-title":"Br J Dermatol."},{"key":"10.1016\/j.abd.2023.03.002_bib0065","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1111\/jdv.15339","article-title":"Severity, heterogeneity, and systemic inflammation in psoriasis","volume":"33","author":"Christophers","year":"2019","journal-title":"J Eur Acad Dermatol Venereol."},{"key":"10.1016\/j.abd.2023.03.002_bib0070","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1590\/abd1806-4841.20183071","article-title":"Evaluation of the occurrence of sexual dysfunction and general quality of life in female patients with psoriasis","volume":"93","author":"Kurizky","year":"2018","journal-title":"An Bras Dermatol."},{"key":"10.1016\/j.abd.2023.03.002_bib0075","doi-asserted-by":"crossref","first-page":"689","DOI":"10.2165\/11536390-000000000-00000","article-title":"Pharmacovigilance activities in 55 low- and middle-income countries: a questionnaire-based analysis","volume":"33","author":"Olsson","year":"2010","journal-title":"Drug Saf."},{"key":"10.1016\/j.abd.2023.03.002_bib0080","doi-asserted-by":"crossref","first-page":"738","DOI":"10.21037\/atm-22-397","article-title":"How long does it take to translate research findings into routine healthcare practice? \u2012 the case of biological drugs for rheumatoid arthritis in Brazil","volume":"10","author":"Lupatini","year":"2022","journal-title":"Ann Transl Med."},{"key":"10.1016\/j.abd.2023.03.002_bib0085","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1080\/09546634.2018.1466023","article-title":"Assessment of psoriasis severity in Brazilian patients with chronic plaque psoriasis attending outpatient clinics: a multicenter, population-based cross-sectional study (APPISOT)","volume":"29","author":"Romiti","year":"2018","journal-title":"J Dermatolog Treat."},{"key":"10.1016\/j.abd.2023.03.002_bib0090","unstructured":"antigo-conitec [Internet]. Brasil. Minist\u00e9rio da Sa\u00fade do Brasil. Protocolo Cl\u00ednico e Diretrizes Terap\u00eauticas da Psor\u00edase. [cited 2023 Feb 8]. Available from: http:\/\/antigo-conitec.saude.gov.br\/images\/Relatorios\/2021\/20211021_Relatorio_652_PCDT_Psoriase.pdf."},{"key":"10.1016\/j.abd.2023.03.002_bib0095","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1002\/JLB.5MR0120-439R","article-title":"Keratinocyte: a trigger or an executor of psoriasis?","volume":"108","author":"Ni","year":"2020","journal-title":"J Leukoc Biol."},{"key":"10.1016\/j.abd.2023.03.002_bib0100","doi-asserted-by":"crossref","first-page":"3176","DOI":"10.2174\/138161211798157649","article-title":"A pathogenetic approach to autoimmune skin disease therapy: psoriasis and biological drugs, unresolved issues, and future directions","volume":"17","author":"Ayroldi","year":"2011","journal-title":"Curr Pharm Des."},{"key":"10.1016\/j.abd.2023.03.002_bib0105","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1111\/j.1468-3083.2011.04410.x","article-title":"The concept of psoriasis as a systemic inflammation: Implications for disease management","volume":"26","author":"Reich","year":"2012","journal-title":"J Eur Acad Dermatol Venereol."},{"key":"10.1016\/j.abd.2023.03.002_bib0110","doi-asserted-by":"crossref","first-page":"7526","DOI":"10.1038\/s41598-019-43899-9","article-title":"Th1, Th17, and Treg responses are differently modulated by TNF-\u03b1 inhibitors and methotrexate in psoriasis patients","volume":"9","author":"Furiati","year":"2019","journal-title":"Sci Rep."},{"key":"10.1016\/j.abd.2023.03.002_bib0115","doi-asserted-by":"crossref","first-page":"1331","DOI":"10.1210\/jcem.85.3.6582","article-title":"Interleukin-6: the endocrine cytokine","volume":"85","author":"Papanicolaou","year":"2000","journal-title":"J Clin Endocrinol Metab."},{"key":"10.1016\/j.abd.2023.03.002_bib0120","doi-asserted-by":"crossref","first-page":"860","DOI":"10.1038\/s41423-021-00644-5","article-title":"Local and systemic effects of IL-17 in joint inflammation: a historical perspective from discovery to targeting","volume":"18","author":"Miossec","year":"2021","journal-title":"Cell Mol Immunol."},{"key":"10.1016\/j.abd.2023.03.002_bib0125","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1007\/s00011-019-01238-8","article-title":"Proinflammatory and anti-inflammatory cytokine profiles in psoriasis: use as laboratory biomarkers and disease predictors","volume":"68","author":"Cataldi","year":"2019","journal-title":"Inflamm Res."},{"key":"10.1016\/j.abd.2023.03.002_bib0130","doi-asserted-by":"crossref","first-page":"1728","DOI":"10.1093\/rheumatology\/kes432","article-title":"Successful use of tocilizumab in a patient with psoriatic arthritis","volume":"52","author":"Hughes","year":"2013","journal-title":"Rheumatology."},{"key":"10.1016\/j.abd.2023.03.002_bib0135","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1007\/s00296-018-4175-1","article-title":"Tocilizumab-induced psoriasis-like eruption resolved by shortening the dose interval in a patient with rheumatoid arthritis: a case-based review","volume":"39","author":"Hayakawa","year":"2019","journal-title":"Rheumatol Int."},{"key":"10.1016\/j.abd.2023.03.002_bib0140","doi-asserted-by":"crossref","first-page":"1887","DOI":"10.4049\/jimmunol.1001227","article-title":"TNF, but not IL-6 and IL-17, is crucial for the development of T cell-independent psoriasis-like dermatitis in Il1rn-\/- mice","volume":"185","author":"Nakajima","year":"2010","journal-title":"J Immunol."},{"key":"10.1016\/j.abd.2023.03.002_bib0145","doi-asserted-by":"crossref","first-page":"81767","DOI":"10.1155\/MI\/2006\/81767","article-title":"Interleukin 6 and 8 levels in plasma and fibroblast cultures in psoriasis","volume":"2006","author":"Zalewska","year":"2006","journal-title":"Mediators Inflamm."},{"key":"10.1016\/j.abd.2023.03.002_bib0150","doi-asserted-by":"crossref","first-page":"137","DOI":"10.3109\/14397595.2016.1174328","article-title":"Serum interleukin-6 levels in response to biologic treatment in patients with psoriasis","volume":"27","author":"Muramatsu","year":"2017","journal-title":"Mod Rheumatol."},{"key":"10.1016\/j.abd.2023.03.002_bib0155","doi-asserted-by":"crossref","first-page":"41","DOI":"10.5114\/ada.2018.78028","article-title":"Serum concentration of interleukin 6 is related to inflammation and dyslipidemia in patients with psoriasis","volume":"37","author":"Pietrzak","year":"2020","journal-title":"Postepy Dermatol Alergol."},{"key":"10.1016\/j.abd.2023.03.002_bib0160","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0151913","article-title":"IL-6 signaling in myelomonocytic cells is not crucial for the development of IMQ-induced psoriasis","volume":"11","author":"Klebow","year":"2016","journal-title":"PLoS One."},{"key":"10.1016\/j.abd.2023.03.002_bib0165","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1038\/s42003-020-01308-2","article-title":"Activation of CD8 T cells accelerates anti-PD-1 antibody-induced psoriasis-like dermatitis through IL-6","volume":"3","author":"Tanaka","year":"2020","journal-title":"Commun Biol."},{"key":"10.1016\/j.abd.2023.03.002_bib0170","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1007\/s10517-022-05497-0","article-title":"IL-6 gene expression as a marker of pathological state in psoriasis and psoriatic arthritis","volume":"173","author":"Sobolev","year":"2022","journal-title":"Bull Exp Biol Med."},{"key":"10.1016\/j.abd.2023.03.002_bib0175","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1007\/s00403-010-1033-8","article-title":"Involvement of IL-17F via the induction of IL-6 in psoriasis","volume":"302","author":"Fujishima","year":"2010","journal-title":"Arch Dermatol Res."},{"key":"10.1016\/j.abd.2023.03.002_bib0180","doi-asserted-by":"crossref","first-page":"1009","DOI":"10.1007\/s00109-021-02073-3","article-title":"Soluble IL-6R-mediated IL-6 trans-signaling activation contributes to the pathological development of psoriasis","volume":"99","author":"Xu","year":"2021","journal-title":"J Mol Med."},{"key":"10.1016\/j.abd.2023.03.002_bib0185","doi-asserted-by":"crossref","DOI":"10.1155\/2014\/964069","article-title":"IL-6 as a druggable target in psoriasis: focus on pustular variants","volume":"2014","author":"Saggini","year":"2014","journal-title":"J Immunol Res."},{"key":"10.1016\/j.abd.2023.03.002_bib0190","doi-asserted-by":"crossref","first-page":"3170","DOI":"10.4049\/jimmunol.0803721","article-title":"IL-6 signaling in psoriasis prevents immune suppression by regulatory T cells","volume":"183","author":"Goodman","year":"2009","journal-title":"J Immunol."},{"key":"10.1016\/j.abd.2023.03.002_bib0195","doi-asserted-by":"crossref","first-page":"1079","DOI":"10.1016\/j.jaci.2015.12.1318","article-title":"Tofacitinib attenuates pathologic immune pathways in patients with psoriasis: a randomized phase 2 study","volume":"137","author":"Krueger","year":"2016","journal-title":"J Allergy Clin Immunol."}],"container-title":["Anais Brasileiros de Dermatologia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0365059623001885?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0365059623001885?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,4,30]],"date-time":"2026-04-30T15:45:55Z","timestamp":1777563955000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0365059623001885"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,1]]},"references-count":39,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2024,1]]}},"alternative-id":["S0365059623001885"],"URL":"https:\/\/doi.org\/10.1016\/j.abd.2023.03.002","relation":{},"ISSN":["0365-0596"],"issn-type":[{"value":"0365-0596","type":"print"}],"subject":[],"published":{"date-parts":[[2024,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Elevated serum IL-6 levels predict treatment interruption in patients with moderate to severe psoriasis: a 6-year real-world cohort study","name":"articletitle","label":"Article Title"},{"value":"Anais Brasileiros de Dermatologia","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.abd.2023.03.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Sociedade Brasileira de Dermatologia. Published by Elsevier Espa\u00f1a, S.L.U.","name":"copyright","label":"Copyright"}]}}